Skip to main content

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.